# US 6,730,686 B1 · Methods for inhibiting oxidative modification of proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,686 B1
- Document ID: US6730686B1
- Status: Granted
- Kind: B1
- Application number: 09/414,877
- Filed: 1999-10-08
- Granted: 2004-05-04
- Earliest claimed: 1995-08-28
- Assignees: Kansas University Medical Center; University of South Carolina
- Inventors: John W. Baynes; Joelle Onorato; Suzanne Thorpe; Raja Khalifah; Billy G. Hudson
- Web page: https://patentgrep.com/patent/US6730686B1

## CPC

- G01N 33/6842: {Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/04: Nitro compounds
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/435: having six-membered rings with one nitrogen as the only ring hetero atom
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4415: Pyridoxine, i.e. Vitamin B6 (pyridoxal phosphate A61K31/675)
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 38/05: Dipeptides
- A61K 38/06: Tripeptides
- A61K 38/07: Tetrapeptides
- C07C 215/50: with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
- C07D 213/66: having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
- C07K 5/06034: {the side chain containing 2 to 4 carbon atoms}
- C07K 5/06052: {Val-amino acid}
- C07K 5/0812: {and aromatic or cycloaliphatic}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6812: {Assays for specific amino acids}
- G01N 2400/02: involving antibodies to sugar part of glycoproteins
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-Amadori AGE formation, and such identified inhibitor compositions. The instant invention also teaches new methods to treat or prevent oxidative modification of proteins, including low density lipoproteins, to treat or prevent lipid peroxidation, and to treat or prevent atherosclerosis, comprising administering an amount effective of one of the compounds of the invention to treat or prevent the disorder.

## Claims

### Claim 1

A method for inhibiting oxidative modification of proteins in a non-hyperglycemic mammal, comprising administering to the non-hyperglycemic mammal an amount effective to inhibit protein oxidative modifications of a compound of the general formula:
wherein R1 is CH2NH2, CH2SH, CH2CH2NH2, CH2CH2SH, or CH2COOH;
R2 and R6 is H, OH, SH, NH2, C 1-18 alkyl, alkoxy or alkene;
R4 and R5 are H, C 1-18 alkyl, alkoxy or alkene;
Y is N or C, such that when Y is N R3 is nothing, and when Y is C, R3 is NO2 or another electron withdrawing group, or salts thereof.

### Claim 2

A method for inhibiting oxidative modification of low density lipoproteins in a non-hyperglycemic mammal, comprising administering to the non-hyperglycemic mammal an amount effective to inhibit low density lipoprotein oxidative modifications of a compound of the general formula:
wherein R1 is CH2NH2, CH2SH, CH2CH2NH2, CH2CH2SH, or CH2COOH;
R2 and R6 is H, OH, SH, NH2, C 1-18 alkyl, alkoxy or alkene;
R4 and R5 are H, C 1-18 alkyl, alkoxy or alkene;
Y is N or C, such that when Y is N R3 is nothing, and when Y is C, R3 is NO2 or another electron withdrawing group, or salts thereof.

### Claim 3

A method for inhibiting lipid peroxidation in a non-hyperglycemic mammal, comprising administering to the non-hyperglycemic mammal an amount effective to inhibit lipid peroxidation of a compound of the general formula:
wherein R1 is CH2NH2, CH2SH, CH2CH2NH2, CH2CH2SH, or CH2COOH;
R2 and R6 is H, OH, SH, NH2, C 1-18 alkyl, alkoxy or alkene;
R4 and R5 are H, C 1-18 alkyl, alkoxy or alkene;
Y is N or C, such that when Y is N R3 is nothing, and when Y is C, R3 is NO2 or another electron withdrawing group, or salts thereof.

### Claim 4

A method for preventing or treating atherosclerosis, comprising administering to a non-hyperglycemic mammal in need thereof an amount effective to prevent or treat atherosclerosis of a compound of the general formula:
wherein R1 is CH2NH2, CH2SH, CH2CH2NH2, CH2CH2SH, or CH2COOH;
wherein when R2 is H, OH, SH, NH2, C 1-18 alkyl, alkoxy or alkene; then R6 is H, SH, NH2, C 1-18 alkyl, alkoxy or alkene; or when R2 is H, OH, SH, NH2, C 1-18 alkoxy then R6 is H, OH SH, NH2, C 1-18 alkyl, alkoxy or alkene;
R4 and R5 are H, C 1-18 alkyl, alkoxy or alkene;
Y is N or C, such that when Y is N R3 is nothing, and when Y is C, R3 is NO2 or another electron withdrawing group, or salts thereof.

### Claim 5

A method for inhibiting the oxidative modification of proteins in a non-hyperglycemic mammal, comprising administering to the non-hyperglycemic mammal an effective amount of pyridoxamine to inhibit the oxidative modification of proteins.

### Claim 6

A method for inhibiting the oxidative modification of low density lipoproteins in a non-hyperglycemic mammal, comprising administering to the non-hyperglycemic mammal an effective amount of pyridoxamine to inhibit the oxidative modification of low density lipoproteins.

### Claim 7

A method for inhibiting lipid peroxidation in a non-hyperglycemic mammal, comprising administering to the non-hyperglycemic mammal an effective amount of pyridoxamine to inhibit lipid peroxidation.
